CTNM
Contineum Therapeutics, Inc. Class A Common Stock
NASDAQ: CTNM · HEALTHCARE · BIOTECHNOLOGY
$12.82
+6.48% today
Updated 2026-04-30
Market cap
$463.34M
P/E ratio
—
P/S ratio
11.15x
EPS (TTM)
$-2.17
Dividend yield
—
52W range
$3 – $16
Volume
0.3M
Contineum Therapeutics, Inc. Class A Common Stock (CTNM) Earnings
Quarterly earnings history, analyst estimates, and stock price reaction.
EPS beat streak
3 of 8
Last 8 quarters
Avg EPS surprise
-29.9%
Last 4 quarters
Revenue YoY growth
—
Most recent quarter
EPS YoY growth
+12.5%
Most recent quarter
Earnings surprise history (last 12 quarters)
Beat estimate Missed estimate
Quarterly EPS and revenue trend
Quarterly revenue EPS (diluted)
How the stock reacts to earnings
Avg 1-day reaction
-2.8%
Last 2 reports
Positive reaction rate
50%
1 of 2 quarters
Largest single-day move
-6.6%
2026-03-05
| Report date | EPS actual | Surprise | Close before | Close after | 1-day reaction |
|---|---|---|---|---|---|
| 2026-03-05 | $-0.49 | +24.6% | $14.86 | $13.88 | -6.6% |
| 2025-10-30 | $-0.45 | +25.0% | $10.90 | $11.01 | +1.0% |
Quarterly earnings history
| Fiscal quarter ending | EPS estimate | EPS actual | Surprise | Revenue | YoY revenue |
|---|---|---|---|---|---|
| 2025-12-31 | $-0.65 | $-0.49 | +24.6% | — | — |
| 2025-09-30 | $-0.60 | $-0.45 | +25.0% | — | — |
| 2025-06-30 | $-0.28 | $-0.62 | -121.4% | — | — |
| 2025-03-31 | $-0.42 | $-0.62 | -47.6% | — | — |
| 2024-12-31 | $-0.43 | $-0.56 | -30.2% | $242000.00 | — |
| 2024-09-30 | $-0.41 | $-0.40 | +2.4% | — | — |
| 2024-06-30 | $-0.35 | $-0.39 | -11.4% | — | — |
| 2024-03-31 | $-0.46 | $-3.55 | -671.7% | — | — |
| 2023-12-31 | $0.00 | $-1.44 | — | — | — |
Frequently asked questions
Has Contineum Therapeutics, Inc. Class A Common Stock beaten earnings estimates?
Contineum Therapeutics, Inc. Class A Common Stock has beaten Wall Street EPS estimates in 3 of its last 8 quarterly reports, with an average EPS surprise of -29.9% over the last 4 quarters.
How does CTNM stock react to earnings?
CTNM stock has moved an average of -2.8% in the trading day following earnings over its last 2 reports, with positive reactions in 50% of those quarters.